-- Funding underlines urgent global need for novel, resistance-proof antimicrobials
JERUSALEM, Israel, October 15, 2025 -- Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, announced today that it raised $25 million in a Series C funding round co-led by Harel Insurance & Finance and the EIC Fund. Existing shareholders Entree Capital, Tal Ventures, Xenia Ventures, and Oriella Limited demonstrated strong confidence in Omnix's approach by taking part in the round alongside new external investors, including Prevail Partners and OurCrowd.
This financing will enable Omnix to complete Phase II proof-of-concept studies for its lead compound, OMN6. The studies will focus on treating life-threatening infections caused by Gram-negative bacteria, particularly Acinetobacter baumannii, including strains resistant to last-line treatments such as carbapenems and colistin. The funding will also support regulatory activities, manufacturing scale-up, and the advancement of Omnix's broader pipeline of engineered antimicrobial peptides. With this latest round of funding, Omnix has raised a total of $43 million since its inception in 2015.
Tomer Goldberg, Vice President, Managing Director Harel Technology Investments at Harel Insurance & Finance, said: "The rise of antibiotic-resistant infections is not just a medical crisis - it's a societal ...
